Seeking Alpha

Salix, Progenics announce date for Relistor advisory committee

  • Salix Pharmaceuticals (SLXP +5.2%) and Progenics Pharmaceuticals (PGNX) finally get a date for an Advisory Committee meeting regarding the companies' appeal of the complete response letter the FDA issued for Relistor in OIC for patients with chronic pain.
  • The committee will convene on March 10-11 next year, after which time action on the appeal is expected within 30 days. (PR)
  • Back in June, SLXP and PGNX noted that they were "optimistic that with the [help of the] FDA and guidance from the Advisory Committee, a path forward" could be found for the drug.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs